MabCure, Inc. aksje

MabCure, Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. It owns a proprietary technology for the generation of monoclonal antibodies against desired antigens, such as cancer markers. The company was formerly known as Smartec Holdings, Inc. and changed its name to MabCure, Inc. in January 2008 to reflect its new business plan. MabCure, Inc. was founded in 2006 and is based in White Plains, New York.